Specifically, compared to EGFRvIII(−) gliomas, the proportion of WHO grade 4 gliomas (EGFRvIII(−):30/56, EGFRvIII(+):14/15, P value = 0.044), IDH wildtype GBMs (EGFRvIII(−):24/56, EGFRvIII(+):12/15, P value = 0.015), IDH wildtype gliomas (EGFRvIII(−):30/56, EGFRvIII(+):15/15, P value = 0.003), and EGFR-amplified gliomas (EGFRvIII(−):4/56, EGFRvIII(+):8/15, P value < 0.001) was significantly higher in EGFRvIII(+) gliomas (Table 1). Here, EGFR is linked to central nervous system cancer.